Back to today’s briefing

Story perspectives

FDA Ends Ozempic Shortage, Compounding Firms' Stocks Plummet

2/22/2025

47 3

Summary

Story summary

The U.S. FDA has officially declared an end to the two-year shortage of Novo Nordisk's semaglutide injections, Ozempic and Wegovy. This pivotal decision restricts compounding pharmacies from creating cheaper alternatives. In a bid to meet soaring demand, Novo Nordisk has poured $6.5 billion into production, causing shares of compounding firms like Hims & Hers to plummet.

History

Historical Context

The FDA's recent decision to end the semaglutide shortage echoes the 1997 FDA Modernization Act, which aimed to streamline drug approvals. This historical context highlights ongoing tensions between pharmaceutical companies and compounding pharmacies, reminiscent of past struggles over drug accessibility and pricing, shaping today's healthcare landscape.

1 of 2

Story summary

The U.S. FDA has officially declared an end to the two-year shortage of Novo Nordisk's semaglutide injections, Ozempic and Wegovy. This pivotal decision restricts compounding pharmacies from creating cheaper alternatives. In a bid to meet soaring demand, Novo Nordisk has poured $6.5 billion into production, causing shares of compounding firms like Hims & Hers to plummet.

1 / 2